基于CiteSpace中医药治疗肝纤维化的可视化分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (2126 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the research status, hotspots, and trends of traditional Chinese medicine in the treatment of hepatic fibrosis in the past 40 years. Methods Articles related to the treatment of hepatic fibrosis with traditional Chinese medicine collected from January 1980 to December 2021 were searched by China national knowledge infrastructure, Wanfang Data, and VIP databases, and CiteSpace 5.8.R3 analysis software was used to perform visual analysis on the trend of the number of published articles, authors, research institutions， and keywords of the retrieved articles. Results A total of 4469 articles from core journals were included, it was in the initial stage before 1997, the number of articles published began to grow rapidly from 1998 to 2004, fell slightly from 2005 to 2007, remained at a high level from 2008 to 2012, fell slightly from 2013 to 2015, and rose briefly from 2016 to 2017. There was a slight decrease from 2018 to 2021. There were 95 core authors whose publications were ≥9, mainly Liu Ping, Liu Chenghai, Liu Cheng, Xu Liming, Lü Zhiping, etc. The main research institutions were medical colleges and affiliated hospitals, among Guangxi University of Chinese medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese medicine, and Shanghai University of Traditional Chinese Medicine were the main research institutions. The top three key words in frequency were rats, hematopoietic stem cells, and cirrhosis. Key words clustering could be divided into three categories: mechanism research, experimental research, and clinical research. The key words with the highest burst intensity were experimental research. Conclusion Traditional Chinese medicine in the treatment of hepatic fibrosis has realized the cross-regional, interagency cooperation, the research focus in the future will focus on traditional Chinese medicine monomer and oxidative stress, anti-oxidation, metabolomics, and other mechanisms, in order to better promote the development of liver fibrosis area.

Key words： Hepatic fibrosis Traditional Chinese medicine therapy CiteSpace Visual analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Ya1 LYU Wenliang2

Cite this article:

ZHANG Ya1 LYU Wenliang2. Visual analysis of traditional Chinese medicine in the treatment of hepatic fibrosis based on CiteSpace[J]. 中国医药导报, 2022, 19(19): 129-132,137.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I19/129

[1] Bataller R，Brenner DA. Liver fibrosis [J]. J Clin Invest，2005，115（2）：209-218.
[2] 徐列明，刘平，沈锡中，等.肝纤维化中西医结合诊疗指南（2019年版）[J].中国中西医结合杂志，2019，39（11）：1286-1295.
[3] Chen C. CiteSpace Ⅱ：Detecting and visualizing emerging trends and transient patterns in scientific literature [J]. J Am Soc Inf Sci，2006，57（3）：359-377.
[4] 陈悦，陈超美，刘则渊，等.CiteSpace知识图谱的方法论功能[J].科学学研究，2015，33（2）：242-253.
[5] 肖准，付亚东，胡永红，等.扶正化瘀方抗肝纤维化主要成分的配伍研究[J].世界科学技术-中医药现代化，2021， 23（5）：1567-1578.
[6] 许燕楠，刘平，慕永平.不同亚型Numb蛋白对肝纤维化相关信号通路的影响[J].临床肝胆病杂志，2021，37（1）：169-172.
[7] 张旭，刘平，慕永平.Notch信号通路与肝纤维化发生发展的关系[J].临床肝胆病杂志，2018，34（1）：181-183.
[8] 慕永平，张笑，徐莹，等.Notch信号通路参与大鼠胆汁性肝纤维化肝祖细胞向胆管上皮细胞分化以及肝纤维化进展[J].中华病理学杂志，2017，46（6）：400-405.
[9] 李品桦，刘旭东，黄露，等.非酒精性脂肪性肝病肝纤维化进展与内皮素-1/一氧化氮的关系[J].临床肝胆病杂志，2021，37（11）：2558-2562.
[10] 刘俊宏，汪龙德，王敏，等.扶正柔肝方联合拉米夫定片治疗慢性乙型肝炎肝纤维化30例临床观察[J].中医杂志，2014，55（15）：1307-1310.
[11] 陈岩岩，周淑娟，夏玉朝，等.化浊抗纤保肝汤联合恩替卡韦对慢性乙型肝炎后肝纤维化患者的临床疗效[J].中成药，2020，42（1）：81-85.
[12] 张冬.鳖甲煎丸辅助治疗乙肝肝纤维化的疗效及对肝功能和脾肿指数及肝纤维化指标的影响[J].当代医学，2021，27（20）：73-75.
[13] 刘旭凌，杨广越，张玮，等.桃红四物汤对CCl4诱导肝纤维化小鼠模型的干预作用及其机制[J].临床肝胆病杂志，2021，37（11）：2563-2568.
[14] 魏涛华，杨文明，唐露露，等.基于网络药理学探讨肝豆扶木汤治疗肝豆状核变性肝纤维化的作用机制及实验验证[J].中国中西医结合杂志，2021，41（8）：981-990.
[15] 赵鑫，吕文良，李娟梅，等.苦杏仁苷抗纤维化作用机制研究进展[J].中华中医药学刊，2020，38（10）：109-112.
[16] 叶凤，曹文富.丹参含药血清对大鼠肝星状细胞增殖及视黄酸受体的影响[J].中药药理与临床，2016，32（2）：128-131.
[17] 韩仕庆，曹文富，何娟，等.丹参含药血清对HSCs中Smo和α-SMA表达的影响[J].中药药理与临床，2015， 31（5）：79-82.
[18] 王国泰，李京涛，魏海梁，等.姜黄素通过抑制TGF-β/smad2信号通路抑制人肝星状细胞纤维化作用研究[J].中国免疫学杂志，2020，36（4）：422-427.
[19] 李桂，董松涛，董占军.基于抗氧化应激作用改善肝纤维化的天然产物的研究概况[J].中国药房，2019，30（19）：2731-2736.
[20] 周志文，李姗，刘湘花，等.中药单体调控氧化应激抗肝纤维化的机制和价值[J].临床肝胆病杂志，2021，37（9）：2198-2202.
[21] 潘富珍，刘定.从活血通络法探讨川芎嗪抗肝纤维化的作用机制研究进展[J].中国医药导报，2021，18（8）：34-37.
[22] 赵瑛，李倩倩.苦参素联合恩替卡韦改善慢性乙型肝炎患者肝纤维化效果观察[J].检验医学与临床，2019，16（20）：3058-3060.
[23] 张珈宁，瞿海燕，张金梦，等.桑黄多糖缓解日本血吸虫感染小鼠氧化应激及肝纤维化的实验研究[J].中国血吸虫病防治杂志，2019，31（6）：615-621.
[24] 王诗洋，王枭，徐祖清，等.苦杏仁苷通过抑制氧化应激及炎症反应减轻四氯化碳诱导的大鼠肝纤维化作用[J].现代免疫学，2020，40（6）：471-475，481.
[25] 章波，檀燕君，黄秋洁，等.代谢组学在中药抗肝纤维化中的研究进展[J].中国临床药理学杂志，2019，35（22）：2918-2922.